EGFR
EGFR (epidermal growth factor receptor) is a gene encoding a transmembrane receptor tyrosine kinase.
EGFR (epidermal growth factor receptor) is a gene encoding a transmembrane receptor tyrosine kinase. Through ligand-dependent receptor activation and phosphorylation, EGFR participates in intracellular signaling pathways that regulate cellular proliferation, survival, migration, and differentiation. Its biological activity is closely associated with downstream signaling involving pathways such as MAPK and AKT, and dysregulated EGFR signaling is relevant to cancer biology.
EGFR is both a disease biomarker and a therapeutic target. Activating EGFR mutations are particularly important in non-small-cell lung cancer, where they guide treatment with EGFR tyrosine-kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib, afatinib, icotinib, and newer agents such as furmonertinib and mefatinib. EGFR amplification, altered receptor signaling, and ligand-mediated activation have also been investigated in glioblastoma, colorectal cancer, breast and esophageal cancers, ovarian cancer, and other solid tumors. Antibody-based approaches, including panitumumab and EGFR-directed bispecific antibodies, extend EGFR targeting beyond small-molecule kinase inhibition.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
119 papers study egfr directly. The themes below are drawn from those 119. 1 paradigm shift and 1 new direction follow.
-
EGFR-Targeted Cancer Therapy : EGFR-directed treatment is moving beyond single agents toward RAF combinations, photoimmunotherapy, peptide-drug conjugates and bispecific T-cell engagers. KRAS-mutant colorectal cancer and acquired EGFR resistance recur as settings where noncanonical targeting is needed. 27 papers · 22.7%
-
EGFR-Mutant Lung Cancer : First-line osimertinib remains central, while amivantamab combinations and EGFR-targeting antibody-drug conjugates broaden treatment options. BRAF fusions, EGFR amplification and treatment-related pneumonitis recur as determinants of resistance, efficacy and safety. 21 papers · 17.6%
-
EGFR TKI Resistance : Early progression and acquired resistance are shifting attention from EGFR alone toward VEGFA/VEGFR2 signaling, ULK1-mediated drug tolerance and MET amplification. New quinazoline and thiazole inhibitors complement combination strategies for EGFR-mutant NSCLC. 21 papers · 17.6%
-
Computational Drug Discovery : Molecular docking, molecular dynamics and network pharmacology are used to nominate EGFR, PARP-1 and other cancer targets, alongside antiviral and anti-inflammatory candidates. The cluster emphasizes computational prioritization, with experimental validation appearing selectively. 17 papers · 14.3%
-
Apoptosis Through EGFR Inhibition : Small-molecule EGFR inhibitors are being paired with PARP-1 or A2AR targeting and optimized against resistant EGFR mutants. Apoptosis and cell-cycle arrest recur as the main efficacy endpoints across lung, breast, colorectal and liver cancer models. 14 papers · 11.8%
-
CNS EGFR-Mutant Lung Cancer : Treatment is increasingly focused on controlling CNS disease through high-dose furmonertinib, afatinib and other EGFR-directed strategies. Drug exposure, skeletal-muscle loss, novel inhibitors and Rb pathway inactivation recur as factors shaping response and transformation. 9 papers · 7.6%
-
Others — Preclinical Solid Tumor Therapies : Experimental therapies span TKI-resistance combinations in RET-positive lung adenocarcinoma, pyroptosis and immune reprogramming in glioblastoma, targeted delivery, and synthetic lethality across solid tumors. No single mechanism or disease dominates. 10 papers · 8.4%
EGFR alteration or abundance does not reliably identify tumors that will respond to EGFR tyrosine-kinase inhibition
The EGFR-suppressing oncogenic RTK-fusion models and patient-derived tumoroid from EGFR-amplified carcinoma of unknown primary independently show that EGFR-directed kinase inhibition need not be the effective consequence of an EGFR-associated tumor state. RTK fusions suppressed transmembrane EGFR signaling, with inhibition of the fusion restoring EGFR activity and promoting survival and drug tolerance, while the EGFR-amplified tumoroid showed only modest growth suppression with EGFR tyrosine-kinase inhibitors but stronger inhibition with an EGFR-targeted antibody-drug conjugate. Together, these findings replace a simple “EGFR alteration means kinase dependence” account with one in which EGFR function and therapeutic vulnerability depend on cellular context and the mode of targeting 42574606Aug 42616271Aug.
EGFR is used as a lysosomal-degradation cargo rather than only as a signaling target
The LAT1-mediated lysosome-targeting chimera platform uses EGFR as one of several oncogenic membrane proteins to be internalized and degraded through a LAT1-dependent lysosomal route. This assigns EGFR a role as a selectively removable surface cargo, distinct from the set’s established uses of EGFR as a kinase, signaling pathway, mutation, biomarker, or inhibitor-binding target, and creates a therapeutic strategy based on eliminating the receptor rather than merely blocking its activity 42545113Aug.
Recent Findings on EGFR
Next-Generation EGFR Targeting: Peptide-drug conjugates, photoimmunotherapy, degraders, and immune engagers are expanding EGFR targeting beyond kinase inhibition. P6-SN38 used EGFR as an internalization gate and suppressed KRAS-mutant colorectal cancer xenografts, while mirabody-IR700 produced light-dependent cytotoxicity in EGFR-positive models 42103029May42526257Jul. LA-LYTAC and UPTAB platforms degraded EGFR with other membrane proteins, supporting modular lysosomal targeting and multivalent degradation 42545113Aug42138807May. New EGFR×CD3 and EGFR×CD16 constructs redirected T cells or natural killer cells against EGFR escape variants and EGFR-mutant lung cancer cells 42152476May42397418Jul. Clinical and mechanistic studies support combination strategies involving EGFR with MET, TGF-β, PI3K, RAF, or chemotherapy, although erlotinib plus RAF inhibition failed to improve survival in pancreatic cancer models 42218660May42102329May42095550May42030284Apr.
EGFR-Mutant NSCLC Treatment: Mefatinib improved progression-free survival over gefitinib in first-line EGFR-mutated non-small-cell lung cancer, particularly in tumors with EGFR L858R, although grade 3 or higher adverse events were more frequent 42586967Aug. Amivantamab-based regimens and the EGFR-targeting antibody-drug conjugate SYS6010 produced objective responses in previously treated EGFR-mutant disease, while weight-tiered dosing preserved comparable pharmacokinetic exposure 42594871Aug42166539May. Lazertinib and high-dose furmonertinib showed intracranial activity after prior EGFR tyrosine-kinase inhibitor exposure or in untreated central nervous system metastases 42670582Aug42379171Jun. Ivonescimab plus chemotherapy extended progression-free survival after third-generation EGFR-TKI progression, but serious treatment-related adverse events were more common than with chemotherapy alone 42636833Aug. EGFR amplification, acquired BRAF fusions, and TROP2-positive drug-tolerant persister cells identify distinct vulnerabilities that may require repeat genomic profiling or combination treatment, while osimertinib-induced pneumonitis remains potentially fatal 42446521Jul42546514Aug42314664Jun42049362Apr.
EGFR-TKI Resistance in NSCLC: Early progression during EGFR-TKI treatment is associated with higher tumor burden, TP53 co-mutation, MET amplification, liver or bone metastases, pleural effusion, and later-line or first-generation TKI use 42536589Jul. Drug-tolerant persister cells acquire adaptive dependencies involving ULK1, autophagy, STC2-driven ERK/Beclin 1 signaling, sphingolipid metabolism, and dNTP homeostasis, creating targets for delaying resistance 42407241Jul42043462Apr41988688Apr41941751Apr. Other studies implicate VEGFA, MET amplification, AREG-mediated EGFR activation, and EGFR-SHC1 fusion signaling in resistance, although high VEGFA predicted poorer outcomes with earlier-generation TKIs but not osimertinib 42231027Jun42381268Jul42393288Jul41874451Mar. Computational and experimental programs continue to produce quinazoline, thiazole, and phytochemical EGFR inhibitors, but their evidence remains mainly preclinical 42672009Aug42645656Aug42102697May.
Molecular Docking and Drug Discovery: Molecular docking, molecular dynamics, network pharmacology, and machine learning are being used to prioritize EGFR-directed compounds across cancer, inflammatory disease, infection, and toxicology studies. Tryptophenolide directly inhibited recombinant EGFR kinase and reduced EGFR, ERK1/2, and JUN phosphorylation in colorectal cancer cells, providing experimental support beyond computational prediction 42595923Aug. Cryptotanshinone also combined docking with cellular and animal experiments, linking EGFR inhibition to reactive oxygen species and ferroptosis in glioma 42348047Jun. Other workflows predicted EGFR interactions for plant compounds, environmental chemicals, peptide candidates, and generated molecules, but several reports explicitly require biochemical or cellular validation 42702742Sep42664210Aug42334505Jun42235269Jun42489643Jul. Itraconazole illustrates the limits of target assignment, because molecular dynamics supported stable binding to SMO but structural instability at EGFR 42470490Jul.
Apoptosis-Directed Cancer Drug Design: Apoptosis-directed EGFR drug design increasingly combines receptor inhibition with blockade of PARP-1, A2AR, CDK-2, JAK2/STAT3, tubulin, or VEGFR-2. Dual EGFR/PARP-1, EGFR/CDK-2, and EGFR/A2AR compounds induced cell-cycle arrest, pro-apoptotic gene expression, and antiproliferative activity in breast or colorectal cancer models 42207930May42200498May42155202May42001586Apr. Sulfonamide-modified butein derivatives inhibited EGFR and JAK2/STAT3 signaling in gefitinib-resistant lung cancer cells, while targeted membranolytic peptides caused apoptosis preferentially in EGFR- and MMP-2-high cells 42044554Apr41920242Apr. Scutellarein, gomisin A, and related natural compounds connected EGFR signaling to oxidative stress, ferroptosis, or PI3K/AKT pathway suppression in glioma and neural injury models 41966746Apr41921766Apr. These studies report promising cytotoxicity and occasional in vivo activity, but their leads still require broader pharmacology and comprehensive in vivo evaluation.
EGFR-Mutant CNS Metastases: High-dose furmonertinib produced systemic and intracranial responses in untreated EGFR-mutated non-small-cell lung cancer with central nervous system metastases, including substantial EGFR mutation clearance in plasma and cerebrospinal fluid 42379171Jun. Afatinib dose reduction to 30 mg and pharmacokinetic analyses address treatment tolerability, while a case with co-occurring EGFR L858R and HER2 amplification illustrates the value of stepwise molecular profiling after brain metastasis 42381340Jul42681853Sep. Clinicogenomic studies identify Rb pathway inactivation, AKT and MYC activation, and subsequent MET up-regulation as features of squamous transformation after EGFR-targeted therapy 42308331Jun. New covalent and deuterated EGFR inhibitors showed activity against resistant EGFR variants in preclinical models, including the L858R/T790M/C797S kinase 41930545Apr41875675Mar.
EGFR-targeting CAR-T cells, implantable microdevices, antibody-linked Auger electron nanoparticles, and biomimetic nanoplatforms are being tested to improve local treatment of solid tumors. These approaches produced regional apoptosis, tumor suppression, pyroptosis, immune reprogramming, or prolonged survival in glioblastoma models, with targeted Auger nanoparticles outperforming nontargeted particles after convection-enhanced delivery 42664321Aug42466899Jul42276782Jun. A brigatinib-based EGFR drug conjugate showed selective activity in pancreatic ductal adenocarcinoma, while CRISPR activation screening identified Egfr selection in lung but not pancreatic tumor initiation 42456413Jul41999750Apr. Clinical work also reported longer disease-free survival with three-year adjuvant icotinib after resection of EGFR-mutated stage II–IIIA lung adenocarcinoma 42660909Aug. RET-positive lung adenocarcinoma models further supported upfront combined driver and MET inhibition to delay bypass resistance, although progression eventually recurred after combination treatment 41921856Apr.
Written from 119 PubMed abstracts, each one cited by PMID above. Published: 2026-08-30. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.